About cisatracurium
Non-depolarizing neuromuscular blocking agent
Used for
- Relaxes skeletal muscles during surgery and other procedures
- Helps control muscle movement during mechanical ventilation in intensive care
Usual adult dose
Given intravenously by specialists; typical initial dose is 0.15–0.2 mg/kg for surgery, with further doses or infusion adjusted to monitoring.
Usual dose in children
For children aged 1 month and older, specialist dosing is typically 0.1–0.15 mg/kg intravenously, adjusted to monitoring and procedure.
Common side effects
- Slow heart rate
- Low blood pressure
- Skin flushing
- Bronchospasm or allergic reactions, rarely
Important warnings
- Causes paralysis, including inability to breathe; requires ventilation and specialist monitoring.
- Does not cause unconsciousness or pain relief; suitable anaesthesia and sedation are required.
- Use neuromuscular monitoring and ensure recovery before breathing support is withdrawn.
- Use caution with neuromuscular disease, electrolyte abnormalities, or severe asthma.
Pregnancy
Use only when clinically necessary; human pregnancy data are limited. Specialist assessment is required.
Breastfeeding
Breastfeeding safety data are limited; ask a clinician about use and timing.
Interactions
- Anaesthetics and other neuromuscular blockers can increase or prolong paralysis.
- Some antibiotics, magnesium, and lithium may increase neuromuscular blockade.
- Phenytoin or carbamazepine may reduce blockade, especially with long-term use.
- Corticosteroids during prolonged intensive care may contribute to muscle weakness.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.